We have previously reported a simple technique that combines microarray data from clinical bladder cancer (BC) specimens with those from a BC cell line (BOY) treated with a pharmacological demethylating agent [5-aza-2'-deoxycytidine (5-aza-dC)] to find candidate genes that have tumor suppressive functions. We focused on the cellular retinolbinding protein 1 (CRBP1) gene that was selected by using the microarray data. As CRBP1 regulates intracellular retinoic acid (vitamin A) homeostasis, which is involved in morphogenesis, and cellular proliferation and differentiation, the loss of CRBP1 could cause tumorigenesis in BC. We hypothesized that the inactivation of the CRBP1 gene through CpG methylation contributes to cell viability, including the migration and invasion activity of human BC cells. After the 5-aza-dC treatment, the mRNA and protein expression levels of CRBP1 markedly increased in all BOY and T24 BC cell lines. Combined bisulfite-restriction analysis and bisulfite DNA sequencing revealed that promoter CpG hypermethylation existed in 28 out of the 65 BCs (43%) and in none of the 16 normal bladder epithelia (NBEs). Conversely, CRBP1 mRNA expression in the BCs was significantly lower than that in the NBEs (0.63±0.11 vs. 4.92±0.80, p<0.0001). We found significant inhibition of cell growth (p<0.0001) and migration (p<0.0001) in the CRBP1 stable transfectants compared to the control cell line, in a cell proliferation and wound-healing assay, respectively. In conclusion, the aberrant CpG hypermethylation of the CRBP1 gene promoter could be involved in the development of BC. We demonstrate here for the first time that the CRBP1 gene could have a tumor suppressive function in BC.
Introduction
Bladder cancer (BC) is among the five most common malignancies worldwide, and it is the second most common tumor of the genito-urinary tract and the second most common cause of death in patients with genito-urinary tract malignancies (1) . Although 70-80% of BCs are initially classified as nonmuscle invasive, ~70% of them recur. Of these recurring tumors, 10-15% proceed to muscle invasion and metastasis (2) . Therefore, it is crucial to find what novel mechanisms are involved in BC invasion and metastasis.
As is often the case with other human malignancies, the transcriptional silencing of tumor suppressor genes through the methylation of CpG islands in promoter regions, is considered to be an important and early stage of carcinogenesis in human BC (3) . We previously developed a simple technique that combines microarray data from clinical BC specimens with those from a BC cell line (BOY) treated with a pharmacological demethylating agent [5-aza-2'-deoxycytidine (5-aza-dC)] (4-6). In these previous studies, we identified 20 genes that were considered to be methylated in human BC (shown here in Table III ). Based on that profile, we demonstrated that the COL1A2 and FHL1 genes have a tumor suppressive function and that they were frequently inactivated in BC due to the CpG hypermethylation of the promoter region (5, 6) . Thus, we believe that our method is quick and efficient in finding the methylated gene profile that is involved in cancer development. In the present study, we focused on the cellular retinol-binding protein 1 (CRBP1), which was among the candidate genes.
Retinol (vitamin A) is a fat-soluble micronutrient and occurs in nature in various forms (retinoids). In vivo, it functions as a form of retinoic acid (RA), which has a close relationship with important cellular functions such as morphogenesis, and cellular proliferation and differentiation (7) . Retinoids are bound to CRBPs (types 1, 2 and 3) in the cytoplasm. CRBP1 is widely distributed throughout the body, whereas CRBP2 and 3 demonstrate tissue-specific expression (8) . Of these three, CRBP1 is thought to be essential for vitamin A homeostasis. The importance of this gene product in vivo was documented in CRBP1 knockout mice, which demonstrated squamous keratinizing metaplasia (9) . The loss of CRBP1 expression due to the CpG hypermethylation of its promoter region has been found in various human cancer cell lines (10) . Studies have also demonstrated that the CpG hypermethylation of the gene promoter is frequently observed in various cancers such as lymphoma, gallbladder and renal cell carcinoma, as well as breast, esophageal, gastric and prostate cancers (11) (12) (13) (14) (15) (16) (17) . In terms of BC, certain studies have reported the promoter hypermethylation of CRBP1. However, they have validated neither the expression levels of CRBP1 transcripts nor its functional role in BC development (11, 18) . Another study has also demonstrated that the mRNA expression levels of CRBP1 were up-regulated in cervical cancer (19) . Thus, the functional role of CRBP1 has not been thoroughly investigated in BC and requires further study.
In the present study, we hypothesized that CRBP1 was densely methylated in its promoter region and had a tumor suppressive function in BC. In order to test this, we examined the methylation status and mRNA expression in BC cell lines and clinical BC specimens by using combined bisulfiterestriction analysis (COBRA) and real-time RT-PCR. In addition, we established stable transfectants of CRBP1 for gain-of-function studies and compared their proliferation, migration, and invasion activities with those of the control BC cell lines.
Materials and methods
Clinical samples. The tissue specimens were from 122 BC patients who underwent transurethral resection (TUR) or radical cystectomy at Kagoshima University Hospital between 2003 and 2008. We also used 25 pathologicallyproven normal bladder epithelium (NBE) samples derived from organ-confined prostate cancer patients who underwent prostatectomy. The patient backgrounds and clinicopathological characteristics are summarized in Table I . Each tumor was staged and graded according to the TNM staging system (20) , the Japanese Urological Association and the Japanese Society of Pathology (21) . Our study was approved by the Bioethics Committee of Kagoshima University and prior written informed consent and approval were given by all patients.
Cell culture and 5-aza-dC treatment. We used two human BC cell lines. BOY was established in our laboratory from an Asian male 66-year-old patient who was diagnosed with stage III bladder cancer with lung metastasis (22) and T24 was obtained from the American Type Culture Collection. These cell lines were maintained in minimum essential medium which was supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin/streptomycin in a humidified atmosphere of 5% CO 2 and 95% air at 37˚C. In order to screen for epigenetic alterations of gene methylation, these cells were treated with 1 μM of the DNA methyltransferase inhibitor, 5-aza-dC (Sigma-Aldrich, St. Louis, MO, USA). Cultured cells were harvested after seven days of exposure to 5-aza-dC, and the genomic DNA and total RNA were extracted.
Nucleic acid extraction. Genomic DNA from the BCs and NBEs was extracted with QIAamp tissue kits (Qiagen, Valencia, CA) after the microdissection of 10-μm-thick paraffin-embedded sections and this was precipitated with ethanol. Total RNA was isolated from the frozen fresh tissues and BOY cells with Isogen (Nippon Gene, Tokyo, Japan) following the manufacturer's instructions. The concentrations of DNA and RNA were determined spectrophotometrically and their integrity was verified by gel electrophoresis. The RNA quality was checked in a BioPhotometer™ (Eppendorf, Tokyo, Japan).
cDNA preparation and conventional RT-PCR. We synthesized first strand cDNA with 1 μg of total RNA using random primers and TaqMan reverse transcription reagents (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Foster City, CA, USA). For conventional RT-PCR, glyceraldehyde-3-phosphate 8 dehydrogenase (GAPDH) was used as the internal control. The primer sequences and RT-PCR conditions are listed in Table II . The PCR products were electrophoresed on 2% agarose gels.
Real-time quantitative RT-PCR. Gene specific PCR products were continuously measured with an Applied Biosystems 7300 Fast Real-Time PCR System following the instructions of the manufacturer. The initial PCR step was a 10-min hold at 95˚C and the 45 cycles consisted of a 15-sec denaturation step at 95˚C followed by 1-min annealing/extension at 60˚C. 
All reactions were performed in triplicate and a negative control lacking cDNA was included. TaqMan ® probes, primers for CRBP1 (P/N: Hs00161252_m1, Applied Biosystems) and human 18S ribosomal RNA (rRNA) (Applied Biosystems), were assay-on-demand gene expression products. The expression of CRBP1 mRNA was normalized to the amount of human 18S rRNA in the same cDNA using the standard curve method provided by the manufacturer.
DNA methylation analysis. In order to screen larger numbers of samples for CRBP1 promoter demethylation, we used COBRA, which produces restriction fragments from bisulfitetreated DNA only if methylation is present (Fig. 1A) . A total of 65 BCs and 16 NBEs were only available for the study, as certain samples had insufficient amounts of tissue for the extraction of enough DNA for analysis. Genomic DNA (100 ng) was subjected to sodium bisulfite modification Table II . Primer sequences and PCR conditions. BstUI restriction enzyme digestion was performed to distinguish methylated and unmethylated alleles. The restriction site (CGCG) is recognized and digested by BstUI when the site is methylated. Both the control BOY and T24 showed four fragments (138, 105, 79 and 69 bp), indicating that these were completely methylated. After treatment with 5-aza-dC, a 391-bp fragment appeared along with digested fragments, indicating that these were partially methylated. * 100-bp DNA ladder.
using the EpiTect Bisulfite Kit (Qiagen). DNA modified with sodium bisulfite was selectively amplified by first-round PCR with the primers Pan-sense 1 (PAN-S1) and Pan-antisense 2 (PAN-AS1), followed by second-round PCR with the primers (PAN-S2 and PAN-AS2), of which neither primer set carried any CpG sites (Fig. 1A) . The primer sequences and PCR conditions are summarized in 
Bisulfite DNA sequencing analysis. Bisulfite-modified DNA was amplified using a pair of universal primers, PAN-S1 and PAN-AS1, followed by a second nested PCR with the primers, PAN-S2 and PAN-AS2, in a total volume of 20 μl. The PCR conditions are shown in Table II . Direct bisulfite DNA sequencing of the PCR products using a forward PAN-S2 primer was carried out following the manufacturer's instructions (Applied Biosystems).
Immunoblotting. Total protein lysate was prepared with a detergent lysis buffer in the presence of a protease inhibitor. The 20 μg of protein lysate were separated by using NuPAGE on a 4-12% Bis-Tris gel (Invitrogen, Tokyo) and transferred into a PVDF membrane. Immunoblotting was done with a diluted (1:200) polyclonal CRBP1 antibody (sc-8786, Santa Cruz Biotechnology, Santa Cruz, CA). After being washed, the membrane was incubated with donkey anti-goat IgG horseradish peroxidase conjugate (Bio-Rad, Hercules, CA). Specific complexes were visualized with an echochemiluminescence detection system (GE Healthcare, Fairfield, CT, USA).
Construction of CRBP1 expression vectors and transfection
to BC cell lines. The CRBP1 vector was constructed by inserting full-length CRBP1 cDNA into the BamHI and XbaI restriction sites of the pBApo-CMV NeoTM vector (Takara Bio, Otsu, Japan). The CRBP1-and the non-targeting (control) vectors were transfected into the BOY and T24 cells by calcium phosphate co-precipitation. Both cells were split and grown in a selective medium with 1000 mg/l of G418. After two weeks, G418-resistant colonies were chosen and expanded in a medium containing 100 mg/l of G418.
XTT assays. For quantification of the cell proliferation of the CRBP1 transfectants, the controls and the wild-type BOY and T24 cells, the absorbance was measured at 492 nm after the cells had been exposed to XTT, which was metabolized by mitochondrial dehydrogenase to yield a formazan dye. In brief, the cells were transferred to 96-well plates at 3x10 3 cells/well and incubated for 72 h. Then, a 50 μl solution of XTT (0.3 mg/ml) that contained 1.25 μM of PMS was added to each well and the absorbance was measured after a further 4 h of incubation at 37˚C.
Wound-healing assay. The CRBP1 transfectants, controls and the wild-type BOY and T24 cells, were used in the 'wound-healing' assay to test the alteration of cell motility and migration. Cells were initially seeded uniformly into 60-mm culture plates with an artificial 'wound' carefully created at 0 h. A P-20 pipette tip was used to scratch the subconfluent cell monolayer. Microphotographs were taken at 0, 6 and 12 h. Quantitative analysis of the percentage of wound healing was calculated using the distance across the wound (n=20) at 0, 6 and 12 h, divided by the distance measured at 0 h for each cell line.
Statistical analysis and annotation of gene function.
The relationship between two groups and the numerical value obtained by real-time RT-PCR was analyzed using the MannWhitney U test. The relationships between three groups and the numerical value were analyzed using the Bonferroniadjusted Mann-Whitney U test. The analysis software used was Expert StatView (version 4, SAS Institute Inc., Cary, NC, USA). The non-adjusted statistical level of significance of p<0.05, corresponded to the Bonferroni-adjusted level of p<0.0167 in the comparisons test comparing the three groups. The molecular function of the up-and down-regulated genes was classified into 17 categories as referenced in the Gene Ontology Consortium (http://www.geneontology.org/ index.shtml), i.e., apoptosis, anatomical structure development, cell cycle, cell differentiation and proliferation, gene expression, metabolic process, response to stimulus, regulation of gene expression, transport, regulation of apoptosis, cell proliferation, signal transduction and transcription, signal transduction, transport, transcription and others. Fig. 1 shows the methylation status of BOY and T24 analyzed with the COBRA assay. As the PCR product contains three 'CGCG' motifs, which are targeted by the restriction enzyme (BstUI), there could be four fragments (Fig. 1B) . These cells were subjected to real-time RT-PCR to evaluate the mRNA expression levels of CRBP1. The expression levels of CRBP1 mRNA were markedly increased in a dose-dependent manner by 5-aza-dC treatment ( Fig. 2A) . Immunoblotting also demonstrated that the 15 kDa CRBP1 protein was restored after 5-aza-dC treatment in both cell lines (Fig. 2B) .
Results

Methylation status and altered CRBP1 expression in 5-aza-dCtreated BC cell lines.
DNA methylation status and mRNA expression of CRBP1 in clinical samples.
Representative results of the COBRA assay in NBE (no. 1) and clinical BC (from nos. 2 to 8) samples are shown in Fig. 3A . A single band of 391 bp was observed in the sample nos. 1, 2 and 4, indicating that these CpG sites were completely unmethylated. The 391-bp band with various fragments was found in the sample nos. 3, 5 and 6 samples, indicating that these CpG sites were partially methylated. Sample nos. 7 and 8 had fragments without the 391-bp band, indicating these CpG sites were completely methylated. In Fig. 3B , we show the results of typical bisulfite DNA sequencing in the BC samples corresponding to COBRA. In sample no. 1, there was a modest 'T' and no 'C' peak at any CpG site, substantiating that this was a completely unmethylated sample, as indicated by COBRA. Sample no. 5, which was diagnosed as partially methylated by COBRA, disclosed a strong 'C' and modest 'T' peak at each CpG site, corroborating that it was partially methylated. In sample no. 7, a strong 'C' and no 'T' peak at any CpG site substantiated that it was a completely methylated sample.
COBRA and bisulfite DNA sequencing revealed that there was promoter CpG hypermethylation in 28 out of the 65 BCs (43%) and in none of the 16 NBEs (0%) (Fig. 3C) . Conversely, CRBP1 mRNA expression in the BCs was significantly lower than that in the NBEs (0.63±0.11 vs. 4.92±0.80, p<0.0001) (Fig. 3C) . We analyzed the relationship between the clinicopathological factors, but there was no correlation between the methylation status or mRNA expression of CRBP1 and the patient characteristics (data not shown).
Identification of CRBP1 expression in transfected cells and effect of CRBP1 overexpression on cell growth. As we found very low expression levels of CRBP1 mRNA in wild-type BOY and T24 cells, we established CRBP1 transfectants from the BOY and T24 cells. The expression levels of CRBP1 mRNA in the BOY/CRBP1 transfectants werẽ 450,000-fold higher than those in the control or wild-type BOY cells, and the levels in the T24/CRBP1 transfectants were 400-fold higher than those in the control or wild-type T24 cells (Fig. 4A) . Immunoblotting vigorously detected a 15-kDa CRBP1 protein in the BOY/CRBP1 transfectants, and it was modestly detected in the T24/CRBP1 transfectants (Fig. 4A) . In order to evaluate the relationship between CRBP1 expression and cell growth, we performed XTT assays using the CRBP1 transfectants, control, and wild-type cells. Three independent XTT assays consistently demonstrated significant growth inhibitions in the CRBP1 transfectants compared to the control, and wild-type cells (% of cell viability in BOY on day 3: 68.8±0.7, 100±1.8 and 95.7±0.8, respectively, p<0.0001, and that in T24: 66.6±0.3, 100±1.8 and 99.5±0.8, respectively, p<0.0001) (Fig. 4B) . In order to examine cellular migration ability, we carried out wound-healing assays using the CRBP1 transfectants in comparison to their counterparts. Three independent wound- healing assays demonstrated significant cell migration inhibitions in the CRBP1 transfectants after 48 h of treatment (% of wound closure in BOY: 59.3±3.8, 89.1±1.9 and 100±10.8, respectively, p<0.0001, and that in T24: 57±7.5, 104.1±0.9 and 100±0.7, respectively, p<0.0001) (Fig. 5) .
Gene expression analysis for CRBP1 overexpression. In order to gain further insight into which genes were affected by the activity of the CRBP1 gene expression, we analyzed the gene expression profile of the CRBP1 transfectants, in which the CRBP1 protein was overwhelmingly expressed (Fig. 4A) . We identified 1039 genes that were up-regulated >2-fold compared to the control transfectant (Fig. 6A ). In contrast, 797 genes were down-regulated <2-fold (Fig. 6B) . The functional annotations of the up-and down-regulated genes were classified into 17 categories (Fig. 6) . Functionally, the up-regulated genes were involved in the metabolic process (23%), response to stimulus (11%), anatomical structure development (10%), regulation of gene expression (7%), transport (7%), regulation of transcription (7%), cell differentiation (6%), regulation of signal transduction (4%), apoptosis (4%), regulation of cell proliferation (3%) and others (18%) (Fig. 6A ). The down-regulated genes were involved in the metabolic process (22%), signal transduction (14%), transport (10%), gene expression (9%), transcription (7%), cell proliferation (6%), regulation of apoptosis (6%), cell cycle (4%) and others (23%) (Fig. 6B) .
Discussion
We have previously demonstrated that our profile for methylated genes in BC is preferable as we used microarray data from two simple hybridizations. In brief, we identified the genes methylated in human BC (Table III) by filtering the subset of genes restored after 5-aza-dC treatment in human BC cell lines from the down-regulated genes in the clinical BCs in our previous microarray (4). Based on this profile, we focused on the CRBP1 gene in this study, and we confirmed that the promoter hypermethylation of CRBP1 was significantly more frequent in BCs than in NBEs. Other sudies have also demonstrated that the promoter hypermethylation of CRBP1 is a frequent event in various cancers, and that it inhibits the transcription of CRBP1 (10-18). However, there have not been many studies on the functional role of CRBP1 in BC. Consistent with previous studies on other malignancies, we also found CRBP1 promoter hypermethylation and the frequent down-regulation of CRBP1 mRNA in human BC. In addition, the demethylating agent restored CRBP1 mRNA expression through the demethylation of the CRBP1 promoter in BC cell lines, suggesting that the inactivation of the CRBP1 gene by the promoter plays an important role in human BC development. The COBRA assays demonstrated that there were various methylation stages (complete and partial methylation as well as unmethylation) in the clinical BCs, suggesting that these degrees of methylation could contribute to a BC phenotype, which defines the malignant potential. These results led us to believe that it would be better to use a combination of RA and demethylating agents, such as aza-dC, for therapeutic strategies in patients with BC. There was no significant relationship in our cohort between the CRBP1 expression and clinicopathological parameters including tumor stage and grade, and patient prognosis. However, a previous study demonstrated that CRBP1 gene expression was correlated with longer survival in laryngeal squamous cell carcinoma (23) . The follow-up period was too short to evaluate prognosis in the present study. It is known that CRBP1 regulates intracellular RA transport, metabolism, and transcriptional activity (7) . The loss of CRBP1 could diminish RA transport and result in blockage of the transcription of RA-responsive genes that regulate cell proliferation. However, previous studies have supported the hypothesis that CRBP1 could be involved in the promotion of apoptosis through an increase in the RA metabolism in breast cancer cell lines (17, 24, 25) . As the suppression of apoptosis played a key role in BC carcinogenesis (26) , the observed low expression of CRBP1 in our study could disrupt the RA-mediated apoptosis pathway in BC. In clinical terms, the functional role of the CRBP1 gene in human cancers still remains controversial. Many studies have shown that it is down-regulated and functions as a tumor suppressor gene (11) (12) (13) (14) (15) (16) (17) (18) , whereas it is up-regulated in cervical cancer (19) . In breast cancer, CRBP1 down-regulation promoted the progression of tumors through the inhibition of RA receptor activity (24) . In terms of BC, RA treatment effectively reduced the recurrence rate and increased the survival time of superficial BC patients (26, 27) . However, there have been no gain-of-function studies on the CRBP1 gene. Therefore, we established CRBP1 transfectants using BC cell lines, and these significantly showed growth and migration inhibition in comparison to the controls. The data suggest that CRBP1 gene expression can cause a tumor suppressive function in BC through the intracellular RA metabolism. Further investigations are necessary to clarify whether these phenomena are critical in the development of BC.
In order to gain further insight into which genes are affected by CRBP1 gene expression, we analyzed the gene expression profile of the CRBP1 transfectants. The functional annotations of the up-regulated genes after CRBP1 transfection were distributed among 17 categories including apoptosis, anatomical structure development, cell cycle, and cell differentiation and proliferation. The up-regulated gene categories in the CRBP1 transfectants include tumor suppressive categories, such as anatomical structure development, cell differentiation and apoptosis. However, the downregulated gene categories include oncogenic categories, such as signal transduction, transcription, cell proliferation and cell cycle. These results suggest that CRBP1 activates other tumor suppressor genes and inactivates oncogenic genes in BC. Further investigations are required to test this hypothesis.
We concluded that the mechanism for CRBP1 downregulation in BC cells occurs through the CpG hypermethylation of the promoter region. To the best of our knowledge, we demonstrate for the first time that the CRBP1 gene can have a tumor suppressive function in human BC. The fact that the restored CRBP1 expression in the transfectants decreased cell growth and migration activity, indicates that this gene is a promising candidate for gene therapy of human BC.
